Literature DB >> 27787866

Podocyte Shape Regulation by Semaphorin 3A and MICAL-1.

Alda Tufro1.   

Abstract

Podocytes are complex epithelial cells with foot processes that are essential for the integrity and function of the kidney glomerular filters. Podocyte foot processes linked by slit diaphragms constitute signaling platforms that tightly regulate the cell shape and the function of the filtration barrier. Semaphorin (Sema) 3A is a class 3 semaphorin secreted by podocytes that has autocrine and paracrine functions in the kidney. We have shown that Sema3A regulates podocyte shape and that excess Sema3A signaling induces glomerular disease and aggravates diabetic nephropathy. MICAL-1 is an actin-binding protein that mediates Sema3A signals in podocytes. This chapter describes the methods used to examine how Sema3A signaling regulates podocyte shape.

Entities:  

Keywords:  F-actin; Immortalized podocytes; MICAL-1; Sema3A; Xanthofulvin; shRNA; siRNA

Mesh:

Substances:

Year:  2017        PMID: 27787866      PMCID: PMC6116512          DOI: 10.1007/978-1-4939-6448-2_28

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression.

Authors:  Moin A Saleem; Michael J O'Hare; Jochen Reiser; Richard J Coward; Carol D Inward; Timothy Farren; Chang Ying Xing; Lan Ni; Peter W Mathieson; Peter Mundel
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

2.  Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes.

Authors:  Claudia Bertuccio; Delma Veron; Pardeep K Aggarwal; Lawrence Holzman; Alda Tufro
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

3.  MICAL-1 is a negative regulator of MST-NDR kinase signaling and apoptosis.

Authors:  Yeping Zhou; Youri Adolfs; W W M Pim Pijnappel; Stephen J Fuller; Roel C Van der Schors; Ka Wan Li; Peter H Sugden; August B Smit; Alexander Hergovich; R Jeroen Pasterkamp
Journal:  Mol Cell Biol       Date:  2011-07-05       Impact factor: 4.272

4.  Syntheses of xanthofulvin and vinaxanthone, natural products enabling spinal cord regeneration.

Authors:  Abram Axelrod; Anders M Eliasen; Matthew R Chin; Katherine Zlotkowski; Dionicio Siegel
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-19       Impact factor: 15.336

5.  Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney.

Authors:  Guillermo Villegas; Alda Tufro
Journal:  Mech Dev       Date:  2002-12       Impact factor: 1.882

6.  Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development.

Authors:  Kimberly J Reidy; Guillermo Villegas; Jason Teichman; Delma Veron; Wa Shen; Juan Jimenez; David Thomas; Alda Tufro
Journal:  Development       Date:  2009-12       Impact factor: 6.868

7.  Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival.

Authors:  F Guan; G Villegas; J Teichman; P Mundel; A Tufro
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

8.  MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion.

Authors:  Jonathan R Terman; Tianyi Mao; R Jeroen Pasterkamp; Hung-Hsiang Yu; Alex L Kolodkin
Journal:  Cell       Date:  2002-06-28       Impact factor: 41.582

9.  Semaphorin3a inhibits ureteric bud branching morphogenesis.

Authors:  Alda Tufro; Jason Teichman; Craig Woda; Guillermo Villegas
Journal:  Mech Dev       Date:  2007-12-28       Impact factor: 1.882

10.  Semaphorin3a promotes advanced diabetic nephropathy.

Authors:  Pardeep K Aggarwal; Delma Veron; David B Thomas; Dionicio Siegel; Gilbert Moeckel; Michael Kashgarian; Alda Tufro
Journal:  Diabetes       Date:  2014-12-04       Impact factor: 9.461

View more
  1 in total

1.  S-Nitrosylation of RhoGAP Myosin9A Is Altered in Advanced Diabetic Kidney Disease.

Authors:  Qi Li; Delma Veron; Alda Tufro
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.